Skip to content
10-Q

Quarterly Report

ALPINE IMMUNE SCIENCES, INC.

0001626199-24-000064

← back to feed
Filed
May 9, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 2, 2024 68.6M sh
Shares Diluted Q1 2024 · Mar 31, 2024 64.03M sh
Shares Diluted Q1 2024 · Mar 31, 2023 47.57M sh
Capex Q1 2024 · Mar 31, 2024 $19K
Capex Q1 2024 · Mar 31, 2023 $93K
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$27.69M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$26.15M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $33.02M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $43.92M
Stockholders Equity Q1 2024 · Mar 31, 2024 $332.7M
Stockholders Equity Q1 2024 · Dec 31, 2023 $327.94M
Stockholders Equity Q1 2024 · Mar 31, 2023 $169.54M
Stockholders Equity Q1 2024 · Dec 31, 2022 $179.42M
Current Liabilities Q1 2024 · Mar 31, 2024 $32.24M
Current Liabilities Q1 2024 · Dec 31, 2023 $41.98M
Total Liabilities Q1 2024 · Mar 31, 2024 $40.94M
Total Liabilities Q1 2024 · Dec 31, 2023 $51.91M
Current Assets Q1 2024 · Mar 31, 2024 $308.25M
Current Assets Q1 2024 · Dec 31, 2023 $330.03M
Total Assets Q1 2024 · Mar 31, 2024 $373.65M
Total Assets Q1 2024 · Dec 31, 2023 $379.85M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.28
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.28
Eps Basic Q1 2024 · Mar 31, 2024 −$0.28
Eps Basic Q1 2024 · Mar 31, 2023 −$0.28
Sga Expense Q1 2024 · Mar 31, 2024 $7.27M
Sga Expense Q1 2024 · Mar 31, 2023 $5.4M
Rd Expense Q1 2024 · Mar 31, 2024 $22.46M
Rd Expense Q1 2024 · Mar 31, 2023 $19.58M
Net Income Q1 2024 · Mar 31, 2024 −$17.92M
Net Income Q1 2024 · Mar 31, 2023 −$13.27M
Operating Income Q1 2024 · Mar 31, 2024 −$22.7M
Operating Income Q1 2024 · Mar 31, 2023 −$15.59M
Revenue Q1 2024 · Mar 31, 2024 $7.03M
Revenue Q1 2024 · Mar 31, 2023 $9.39M